Shen, L., A. Orillion, R. Pili. (2016) “Histone deacetylase inhibitors as immunomodulators in cancer therapeutics.” Epigenomics. 2016 Mar 7:1-14. doi: 10.2117/epi.15.118.
Park J., S. Thomas, and P. Munster. (2015). “Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy”. Epigenomics. 7: 641–652
Butt A., and K. Mills (2014). “Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.” Oncogene. 33: 4623–4631.
Forde PM, J.R. Brahmer, and R.J. Kelly. (2014). “New strategies in lung cancer: epigenetic therapy for non-small cell lung cancer.” Clin. Cancer Res. 20: 2244–8.
Kim, K., A. Skora, et al. (2014). “Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells.” PNAS. 2014 July 28. Online.
Brahmer J, and D. Pardoll. (2013). “Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer.” Cancer Immunol Res. 1: 85–91.
Najjar Y, and J. Finke. (2013). “Clinical Perspectives on Targeting of Myeloid Derived Suppressor Cells in the Treatment of Cancer.” Front. Oncol. 3.
Pili, R., L. Shen, et al. (2013). “Phase I study of high-dose interleukin 2, aldesleukin, in combination with the histone deacetylase inhibitor, entinostat, in patients with metastatic renal cell carcinoma: Safety data.” ASCO Genitourinary poster.
Youn J-I, V. Kumar, et al. (2013). “Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer.” Nat. Immunol. 14: 211–220.
Zhu S., C. Denman, et al. (2013). “The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells.” Pharm. Res. 32: 779–92.
Shen, L., M. Ciesielksi, et al. (2012). “Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.” PLoSOne. 7(1):1-14.
Buglio, D., N. Kashkhely, et al. (2011). “HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma.” Blood. 117(10): 2910 – 2917.
Juergens RA, J. Wrangle, et al. (2011). “Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.” Cancer Discov. 1: 598–607